CorMedix Inc. (CRMD) 宣布,其评估Rezzayo®用于预防异基因造血干细胞移植患者侵袭性真菌病的三期RESPECT临床试验,已获得积极的顶线结果。
该试验达到了其主要疗效终点,数据显示Rezzayo®在预防侵袭性真菌病方面表现出显著优势。此项积极结果为该药物在此高风险患者群体中的应用提供了强有力的支持。
CorMedix Inc. (CRMD) 宣布,其评估Rezzayo®用于预防异基因造血干细胞移植患者侵袭性真菌病的三期RESPECT临床试验,已获得积极的顶线结果。
该试验达到了其主要疗效终点,数据显示Rezzayo®在预防侵袭性真菌病方面表现出显著优势。此项积极结果为该药物在此高风险患者群体中的应用提供了强有力的支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.